An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Hydrocodone | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Magnesium sulfate | The therapeutic efficacy of Dimethyltryptamine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Dimethyltryptamine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Orphenadrine | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Pramipexole | Dimethyltryptamine may increase the sedative activities of Pramipexole. |
| Ropinirole | Dimethyltryptamine may increase the sedative activities of Ropinirole. |
| Rotigotine | Dimethyltryptamine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Dimethyltryptamine. |
| Sodium oxybate | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Thalidomide | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Dimethyltryptamine. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Dimethyltryptamine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with (S)-Warfarin. |
| Mirtazapine | Dimethyltryptamine may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Dimethyltryptamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Dimethyltryptamine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Dimethyltryptamine is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Alaproclate. |
| Methylene blue | Dimethyltryptamine may increase the serotonergic activities of Methylene blue. |
| Zopiclone | The risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Dimethyltryptamine. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Dimethyltryptamine. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Dimethyltryptamine. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Dimethyltryptamine. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Dimethyltryptamine. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Dimethyltryptamine. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Dimethyltryptamine. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Dimethyltryptamine. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Dimethyltryptamine. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Dimethyltryptamine. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Dimethyltryptamine. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Dimethyltryptamine. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Dimethyltryptamine. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Dimethyltryptamine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Dimethyltryptamine. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Dimethyltryptamine. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Dimethyltryptamine. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Dimethyltryptamine. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Dimethyltryptamine. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Dimethyltryptamine. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Dimethyltryptamine. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Dimethyltryptamine. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Dimethyltryptamine. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Dimethyltryptamine. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Dimethyltryptamine. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Dimethyltryptamine. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Dimethyltryptamine. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with Dimethyltryptamine. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Dimethyltryptamine. |
| Metocurine iodide | The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Dimethyltryptamine. |
| Secobarbital | The risk or severity of CNS depression can be increased when Secobarbital is combined with Dimethyltryptamine. |
| Methocarbamol | The risk or severity of CNS depression can be increased when Methocarbamol is combined with Dimethyltryptamine. |
| Triprolidine | The risk or severity of CNS depression can be increased when Triprolidine is combined with Dimethyltryptamine. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Dimethyltryptamine. |
| Meperidine | The risk or severity of CNS depression can be increased when Meperidine is combined with Dimethyltryptamine. |
| Metharbital | The risk or severity of CNS depression can be increased when Metharbital is combined with Dimethyltryptamine. |
| Quinine | The risk or severity of CNS depression can be increased when Quinine is combined with Dimethyltryptamine. |
| Methohexital | The risk or severity of CNS depression can be increased when Methohexital is combined with Dimethyltryptamine. |
| Gallamine triethiodide | The risk or severity of CNS depression can be increased when Gallamine triethiodide is combined with Dimethyltryptamine. |